Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial.
Rediti M, Fimereli D, Mileva M, Wimana Z, Venet D, Flamen P, Guiot T, de Vries EGE, Schröder CP, Menke-van der Houven van Oordt CW, Maetens M, Majjaj S, Larsimont D, Rothé F, Sotiriou C, Gebhart G. Rediti M, et al. Among authors: majjaj s. Clin Cancer Res. 2024 Oct 29. doi: 10.1158/1078-0432.CCR-24-1007. Online ahead of print. Clin Cancer Res. 2024. PMID: 39470686
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Venet D, et al. Among authors: majjaj s. Clin Cancer Res. 2021 Oct 15;27(20):5607-5618. doi: 10.1158/1078-0432.CCR-21-1317. Epub 2021 Jul 28. Clin Cancer Res. 2021. PMID: 34321278
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00.
Joaquin Garcia A, Rediti M, Venet D, Majjaj S, Kammler R, Munzone E, Gianni L, Thürlimann B, Laáng I, Colleoni M, Loi S, Viale G, Regan MM, Buisseret L, Rothé F, Sotiriou C. Joaquin Garcia A, et al. Among authors: majjaj s. Clin Cancer Res. 2023 Dec 1;29(23):4908-4919. doi: 10.1158/1078-0432.CCR-23-1267. Clin Cancer Res. 2023. PMID: 37733800
Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.
Desmedt C, Majjaj S, Kheddoumi N, Singhal SK, Haibe-Kains B, El Ouriaghli F, Chaboteaux C, Michiels S, Lallemand F, Journe F, Duvillier H, Loi S, Quackenbush J, Dekoninck S, Blanpain C, Lagneaux L, Houhou N, Delorenzi M, Larsimont D, Piccart M, Sotiriou C. Desmedt C, et al. Among authors: majjaj s. Clin Cancer Res. 2012 Feb 15;18(4):1004-14. doi: 10.1158/1078-0432.CCR-11-0383. Epub 2012 Jan 10. Clin Cancer Res. 2012. PMID: 22235100 Free PMC article.
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL. Hanker AB, et al. Among authors: majjaj s. Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. doi: 10.1158/1078-0432.CCR-16-2287. Epub 2017 Apr 5. Clin Cancer Res. 2017. PMID: 28381415 Free PMC article.
Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F, Majjaj S, Venet D, Rothé F, Pingitore J, Boeckx B, Marchio C, Clatot F, Bertucci F, Mariani O, Galant C, Eynden GVD, Salgado R, Biganzoli E, Lambrechts D, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C, Desmedt C. Richard F, et al. Among authors: majjaj s. Clin Cancer Res. 2020 Dec 1;26(23):6254-6265. doi: 10.1158/1078-0432.CCR-20-2268. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943456
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.
Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C. Rothé F, et al. Among authors: majjaj s. PLoS One. 2011;6(6):e20980. doi: 10.1371/journal.pone.0020980. Epub 2011 Jun 29. PLoS One. 2011. PMID: 21738599 Free PMC article.
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.
Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart M, Detours V, Sotiriou C, Haibe-Kains B. Fumagalli D, et al. Among authors: majjaj s. BMC Genomics. 2014 Nov 21;15(1):1008. doi: 10.1186/1471-2164-15-1008. BMC Genomics. 2014. PMID: 25412710 Free PMC article.
Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C. Desmedt C, et al. Among authors: majjaj s. J Clin Oncol. 2016 Jun 1;34(16):1872-81. doi: 10.1200/JCO.2015.64.0334. Epub 2016 Feb 29. J Clin Oncol. 2016. PMID: 26926684
25 results